Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2000

View Archived Issues

Dynavax and Aventis Pasteur enter strategic collaboration to develop novel vaccines

PPD Discovery and Agouron establish alliance seeking new anti-HIV targets

Nasal osteoporosis product enters U.S. clinical trials

Lilly and Alkermes to develop pulmonary form of human growth hormone

Start of phase II trials for Resten-NG announced

Human Genome Sciences and Praecis enter agreement for small-molecule drug discovery

Icos year-end 1999 marked by robust clinical activity

Interneuron's Q1 2000 marked by strong licensing activities

Patients now being enrolled in Barr's phase III trial of CyPat

OHSU study will test efficacy of COX-2 inhibitor in colon cancer

Novartis bisphosphonate (Zometa) granted priority review status

SmithKline Beecham and ImClone Systems to collaborate on meningitis vaccine

Successful application of Zycos's novel DNA technology in early clinical trials

Improved topical formulations of aciclovir developed at Recordati

Nastech claims formulations of sildenafil for nasal delivery

Kissei compounds display excellent beta3-adrenoceptor-stimulating effects

Dual AT1/ETA receptor antagonists from BMS, their preparation, use and pharmaceutical compositions

CeNeS and Bioglan to codevelop aerosol analgesic

Synthesis and use of new CRF antagonists disclosed by DuPont

Warner-Lambert presents new neuroprotective quinoxaline-2-ones

NXY-059 and ciclosporin evaluated for mechanisms underlying neuroprotective effects

Nonanticoagulant heparin derivative attenuates intracerebral hemorrhage-induced brain edema

FDA to review Schering-Plough's BLA for PEG-Intron

Bayer and marketing partners introduce new fluoroquinolone in Spain

German firm launches important new drug on the domestic market

CGRP gene transfer proves beneficial in rabbit model of subarachnoid hemorrhage

Sibrafiban no better than aspirin in final analysis of SYMPHONY study

Stimulation of HAMA with radiolabeled MAb appears to confer survival advantage in ovarian cancer